Front page

Cancer and HIV, clinical trials that could lead to interesting news in 2023

During 2023 there could be interesting – and important – news from the point of clinical pharmacological studies.

To announce the news that could arrive was the scientific journal Nature Medicine, which asked some experts to hypothesize what could happen, in their field, during these months.

And here, then, that there could be significant news from the point of view of some types of tumors, for HIV or for degenerative diseases such as Parkinson and Alzheimer.

freepik
Pharmacological clinical trials that could bring interesting news in 2023
During 2023 there could be interesting – and important – news from the point of clinical pharmacological studies. To announce the news that could arrive was the scientific journal Nature Medicine, which asked some experts to hypothesize what could happen, in their field, during these months. Let's find out what news there could be for some diseases that affect millions of people in the world.
freepik
What's new about Alzheimer
According to Allan Levey, dean of the Department of Neurology of Emory University, further studies and analyzes on the lecanumab could further confirm the efficacy and safety of this drug. In detail, it is a drug that should have the ability to slow the progression of symptoms associated with Alzheimer.
freepik
What's new about Covid in patients with HIV
We still wonder what effectiveness mRna vaccines can have against Covid in subjects suffering from Hiv but also other diseases that can somehow increase the risk of developing severe forms of Covid. During 2023, the answers of a study started two years earlier in sub-Saharan Africa should arrive. This was confirmed by Glenda Gray, President and Ceo of the South Africa Medical Research Council.
freepik
News on drug therapies against Parkinson disease
According to the neurologist and director of the Center for Movement Disorders at the University of Michigan, Roger Albin, the drug may exenatide have excellent abilities to slow the symptoms of Parkinson disease. Currently this drug is used as an antidiabetic but could also have an effect on some neurodegenerative diseases.
freepik
Pharmacological innovations for the treatment of ovarian cancer
According to Robert Coleman, scientific director of US Oncology Research, the drug could mirvetuximab soravtansine prove to be an excellent strategy to treat ovarian cancer in women who have failed the first lines of therapies. The drug could also pave the way for greater use of antibodies in the field of gynecological oncology.
freepik
The pharmacological news regarding circulating tumor cells
Nicola Aceto, an expert in molecular oncology at the Zurich ETH , thinks that the digoxina, used in the cardiovascular field, could open the door to the development of new drugs for the prevention of the formation of tumor metastases.
Informativa ai sensi della Direttiva 2009/136/CE: questo sito utilizza solo cookie tecnici necessari alla navigazione da parte dell'utente in assenza dei quali il sito non potrebbe funzionare correttamente.